Loading…
Loading…
See exactly how PRF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PRF and 80,000+ other tickers.
The Invesco RAFI US 1000 ETF, referred to as the Fund, is designed to emulate the performance of the RAFI Fundamental Select US 1000 Index. It typically allocates at least 90% of its total assets to the common stocks composing this Index. The Index itself is crafted to track prominent U.S. equities, chosen according to four fundamental indicators of company size: book value, cash flow, sales, and dividends. The one thousand equities demonstrating the highest fundamental strength receive weighting based on their respective fundamental scores. Both the Fund and its underlying Index undergo an…
Integrated Wealth Concepts LLC lifted its holdings in shares of Invesco RAFI US 1000 ETF (NYSEARCA:PRF) by 32.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,618 shares of the company's stock after buying an additional 10,327 shares
On September 2, TMX VettaFi Head of Research Todd Rosenbluth appeared on the Schwab Network to discuss ETF inflows nearing record highs in 2026 and the 50th anniversary of the first-ever index fund, the Vanguard 500 Index Fund.
As valuations become increasingly stretched in today's concentrated market, investors may be wondering where to break away from the typical market-cap weighted approach. Fundamental indexing can do just that, and investors appear to be gravitating to this methodology given the latest asset accumulation data.
New structure designed to enable direct strategic investment, partnerships, and commercial collaborations GridFeed built on validated AI technology and commercial engagements with leading renewable energy companies Platform to be showcased to more than 2,500 energy-market professionals at Energy Trading Week Europe in London TEL AVIV, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd.
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second half of 2026